TABLE III.
Agent and reference (study) | Design | Intervention | Pts (n) | ORR (%) | PFS (months) | OS (months) | Quality of life |
---|---|---|---|---|---|---|---|
Bevacizumab | |||||||
Herbst et al.,200735 | Randomized phase II |
Docetaxel–pemetrexed with bevacizumab 15 mg/kg | 40 | 12.5 | 4.8 HR: 0.66; 95% CI: 0.38 to 1.16 |
12.6 HR: 0.71; 95% CI: 0.41 to 1.21 |
Not assessed. |
Erlotinib with bevacizumab 15 mg/kg | 39 | 17.9 | 4.4 HR: 0.72; 95% CI: 0.42 to 1.23 |
13.7 HR: 0.78; 95% CI: 0.46 to 1.31 |
|||
Docetaxel–pemetrexed with placebo | 41 | 12.2 | 3.0 | 8.6 | |||
Herbst et al.,201136 (BeTa) | Phase III | Erlotinib with bevacizumab 15 mg/kg | 319 | 13 | 3.4 | 9.3 | Not assessed. |
Erlotinib with placebo | 317 | 6 | 1.7 HR: 0.62; 95% CI: 0.52 to 0.75 |
9.2 HR: 0.97; 95% CI: 0.80 to 1.18 |
|||
Cortot et al.,201637 (ULTIMATE) | Randomized phase III |
Paclitaxel (weekly) with bevacizumab 10 mg/kg | 111 | 22.5 | 5.4 | 9.9 | Not assessed. |
Docetaxel | 55 | 5.5 p=0.006 |
3.9 HR: 0.62; 95% CI: 0.44 to 0.87 |
11.4 HR: 1.15; p=0.49 |
|||
Bennouna et al.,201740 (AVaALL) | Phase III | Chemotherapy with bevacizumab | 485 in total | 9.7 | 4.9 HR: 0.85; 90% CI: 0.72 to 1.0 |
11.9 HR: 0.84; 90% CI: 0.71 to 1.0 |
|
Chemotherapy alone | 6.7 | 3.8 | 10.2 | ||||
Garon et al.,201438 (REVEL) | Phase III | Docetaxel with ramucirumab | 628 | 23 | 4.5 | 10.5 | |
Docetaxel with placebo | 625 | 14 | 3.0 HR: 0.76; 95% CI: 0.68 to 0.86 |
9.1 HR: 0.86; 95% CI: 0.75 to 0.98 |
|||
Aflibercept | |||||||
Ramlau et al.,201239 (VITAL) | Phase III | Docetaxel with aflibercept | 456 | 23.3 | 5.2 HR: 0.82; 95% CI: 0.72 to 0.94 |
10.1 HR: 1.01; 95% CI: 0.87 to 1.17 |
No differences observed using the Lung Cancer Symptom Scale. |
Docetaxel with placebo | 457 | 8.9 | 4.1 | 10.4 |
Pts = patients; ORR = objective response rate; PFS = progression-free survival; OS = overall survival; HR = hazard ratio; CI = confidence interval.